News
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback